-
Chiesi’s Rare Disease Strategy Expands to Genetic Meds via Alliance With CRISPR Startup Arbor
10 Oct 2025 23:15 GMT
… takes the company into genetic medicines.
Chiesi Global Rare … genetic medicines do reduce oxalate levels, but they’re chronic therapies — Alnylam … in a lab and genetically engineered cells are infused … inside the patient. Its genetic cargo is encapsulated within …
-
Alnylam (ALNY) Reports 238% Growth in Amvuttra Since February Launch, RBC Raises Price Target
04 Oct 2025 03:39 GMT
… maintained its Outperform rating for Alnylam Pharmaceuticals, Inc. (NASDAQ … the firm believes that Alnylam Pharmaceuticals, Inc. (NASDAQ: … about $2.5 billion. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY … approved medications for rare genetic illnesses. While we …
-
Global RNA-Based Therapies Market to Reach US$213.54B by 2033, Driven by Genetic & Rare Disease Innovations
29 Sep 2025 12:30 GMT
… The increasing prevalence of rare genetic disorders, cancers, and infectious … regulatory frameworks and increased genetic screening and testing contribute to … ?
Company Insights
• Sarepta Therapeutics
• Alnylam Pharmaceuticals
• NS Pharma
• Pfizer
• …
-
Alnylam Pharma joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine
20 Sep 2025 06:31 GMT
… LLC (NashBio), announced Alnylam Pharmaceuticals, Inc. (Alnylam) as a member of … for Genomic Discovery (AGD). Alnylam, a pioneer in RNA … research at Alnylam. "We rely on human genetics to guide … into rare and complex genetic traits.
The AGD dataset …
-
Beyond The Numbers: 28 Analysts Discuss Alnylam Pharmaceuticals Stock
19 Sep 2025 14:58 GMT
… to Know About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a … across various therapeutic areas: genetic medicines; cardio-metabolic diseases; … commercialized under collaboration partnerships.
Alnylam Pharmaceuticals: Financial Performance Dissected …
-
Moderna settles Alnylam patent lawsuits over COVID vaccine technology
19 Sep 2025 02:54 GMT
… accused it of misusing Alnylam Pharmaceuticals' patented … .
Cambridge, Massachusetts-based Alnylam first sued Moderna for … Alnylam's lipid nanoparticle (LNP) technology to deliver genetic … material into the body.
Alnylam requested a …
-
Should You Add Alnylam Pharmaceuticals (ALNY) to Your Portfolio?
02 Sep 2025 13:48 GMT
… such as Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Alnylam Pharmaceuticals, … stated the following regarding Alnylam Pharmaceuticals, Inc. (NASDAQ … protein at the genetic level. The company … Buy According to Billionaires? Alnylam Pharmaceuticals, Inc. (NASDAQ …
-
Roche And Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial For People With Uncontrolled Hypertension
30 Aug 2025 17:08 GMT
… ROG; OTCQX: RHHBY) and Alnylam (Nasdaq: ALNY) today announced … Ang) II. Zilebesiran utilizes Alnylam's Enhanced Stabilization … and co-commercialized by Alnylam and Roche. Zilebesiran Phase … messenger RNA (mRNA) – the genetic precursors – that encode for …
-
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial
30 Aug 2025 15:59 GMT
… messenger RNA (mRNA) – the genetic precursors – that encode for disease … of patients with genetic and other diseases.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY … successfully execute on its “Alnylam P5x25” strategy; Alnylam’s ability to discover …
-
Scenic Enters License And Research Agreement With Alnylam
26 Aug 2025 09:28 GMT
… license and research agreement with Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) to … 's capacity to deliver genetic insights that drive novel therapeutic … radical new approach to treating genetic disorders. Instead of targeting the …
About
© 1995-2025